Status:
NOT_YET_RECRUITING
Preoperative Daptomycin Prophylaxis in Two-Stage Exchange Arthroplasty: A Prospective, Randomized, Double-Blinded Trial
Lead Sponsor:
Chang Gung Memorial Hospital
Conditions:
Periprosthetic Joint Infection
Eligibility:
All Genders
18-90 years
Phase:
NA
Brief Summary
The gold standard for treating prosthetic joint infection (PJI) is two-stage exchange arthroplasty. This includes the first stage of debridement and removal of the artificial joint, and the second sta...
Eligibility Criteria
Inclusion
- Patients aged 18 or older with an infection that meets the 2018 International Consensus Meeting (ICM) criteria7 at the time of the first-stage resection arthroplasty with a gram-positive organism, especially MRSA.
- Will undergo a second stage of reimplantation.
Exclusion
- Patients with a fungal infection or culture-negative infections
- Known allergies to Cefazolin, Daptomycin, or Vancomycin.
- Currently receiving surgical treatment for acute postoperative or acute hematogenous PJI.
- Chronic kidney disease (Creatinine Clearance Rate \[CCR\] \< 30 ml/min/1.73m2)
Key Trial Info
Start Date :
August 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 31 2026
Estimated Enrollment :
184 Patients enrolled
Trial Details
Trial ID
NCT06189885
Start Date
August 1 2024
End Date
July 31 2026
Last Update
January 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City, Taiwan, 833